Amedeo Smart

Free Medical Literature Service



Gastric Cancer

  Free Subscription

Articles published in
Clin Cancer Res
    June 2022
  1. YUKAMI H, Kawazoe A, Lin YT, Koyama S, et al
    Updated efficacy outcomes of anti-PD-1 antibodies plus multikinase inhibitors for advanced gastric cancer patients with or without liver metastases in clinical trials.
    Clin Cancer Res. 2022 Jun 9. pii: 704845. doi: 10.1158/1078-0432.CCR-22-0630.
    >> Share

  2. LEE KW, Van Cutsem E, Bang YJ, Fuchs CS, et al
    Association of Tumor Mutational Burden with Efficacy of Pembrolizumab{plus minus}Chemotherapy as First-Line Therapy for Gastric Cancer in the Phase III KEYNOTE-062 Study.
    Clin Cancer Res. 2022 Jun 3. pii: 699374. doi: 10.1158/1078-0432.CCR-22-0121.
    >> Share

    April 2022
  3. WANG J, Kunzke T, Prade VM, Shen J, et al
    Spatial metabolomics identifies distinct tumor-specific subtypes in gastric cancer patients.
    Clin Cancer Res. 2022 Apr 8. pii: 694328. doi: 10.1158/1078-0432.CCR-21-4383.
    >> Share

    September 2021
  4. HUANG H, Brekken RA
    Location matters: Profiling diffuse type gastric cancer at the single cell level.
    Clin Cancer Res. 2021 Sep 23. pii: 1078-0432.CCR-21-2935.
    >> Share

    August 2021
  5. JEONG HY, Ham IH, Lee SH, Ryu D, et al
    Spatially distinct reprogramming of the tumor microenvironment based on tumor invasion in diffuse-type gastric cancers.
    Clin Cancer Res. 2021 Aug 12. pii: 1078-0432.CCR-21-0792.
    >> Share

  6. JOGO T, Nakamura Y, Shitara K, Bando H, et al
    Circulating Tumor DNA Analysis Detects FGFR2 Amplification and Concurrent Genomic Alterations Associated with FGFR Inhibitor Efficacy in Advanced Gastric Cancer.
    Clin Cancer Res. 2021 Aug 10. pii: 1078-0432.CCR-21-1414.
    >> Share

    July 2021
  7. MOUTAFI M, Rimm DL
    Putting the Microenvironment into the Immunotherapy Companion Diagnostic.
    Clin Cancer Res. 2021;27:3812-3814.
    >> Share

  8. DE CLERCQ NC, van den Ende T, Prodan A, Hemke R, et al
    Fecal Microbiota Transplantation from Overweight or Obese Donors in Cachectic Patients with Advanced Gastroesophageal Cancer: A Randomized, Double-blind, Placebo-Controlled, Phase II Study.
    Clin Cancer Res. 2021;27:3784-3792.
    >> Share

    June 2021
  9. OPENSHAW MR, Pinato DJ, Valeri N
    Back from the Brink: EGFR Inhibition in Gastroesophageal Cancer.
    Clin Cancer Res. 2021;27:2964-2966.
    >> Share

  10. PENG Z, Wei J, Wang F, Ying J, et al
    Camrelizumab Combined with Chemotherapy Followed by Camrelizumab plus Apatinib as First-line Therapy for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma.
    Clin Cancer Res. 2021;27:3069-3078.
    >> Share

  11. CORSO S, Pietrantonio F, Apicella M, Migliore C, et al
    Optimized EGFR Blockade Strategies in EGFR Addicted Gastroesophageal Adenocarcinomas.
    Clin Cancer Res. 2021;27:3126-3140.
    >> Share

    April 2021
  12. WIEDERMANN U, Garner-Spitzer E, Chao Y, Maglakelidze M, et al
    Clinical and immunologic responses to a B-cell epitope vaccine in HER2/neu overexpressing advanced gastric cancer patients - results from Phase 1b trial IMU.ACS.001.
    Clin Cancer Res. 2021 Apr 20. pii: 1078-0432.CCR-20-3742.
    >> Share

    A PERFECT biomarker-focused study of neoadjuvant IO for esophagogastric cancer.
    Clin Cancer Res. 2021 Apr 6. pii: 1078-0432.CCR-21-0324.
    >> Share

  14. WAINBERG ZA, Fuchs CS, Tabernero J, Shitara K, et al
    Efficacy of Pembrolizumab Monotherapy for Advanced Gastric/Gastroesophageal Junction Cancer with Programmed Death Ligand 1 Combined Positive Score >/=10.
    Clin Cancer Res. 2021;27:1923-1931.
    >> Share

    March 2021
  15. LEI M, Siemers NO, Pandya D, Chang H, et al
    Analyses of PD-L1 and Inflammatory Gene Expression Association with Efficacy of Nivolumab{plus minus}Ipilimumab in Gastric Cancer/Gastroesophageal Junction Cancer.
    Clin Cancer Res. 2021 Mar 29. pii: 1078-0432.CCR-20-2790.
    >> Share

    February 2021
  16. LEE IS, Lee H, Hur H, Kanda M, et al
    Transcriptomic Profiling Identifies A Risk Stratification Signature for Predicting Peritoneal Recurrence and Micrometastasis in Gastric Cancer.
    Clin Cancer Res. 2021 Feb 8. pii: 1078-0432.CCR-20-3835.
    >> Share

    December 2020
  17. NAKAJIMA TE, Kadowaki S, Minashi K, Nishina T, et al
    Multicenter phase I/II study of nivolumab combined with paclitaxel plus ramucirumab as second-line treatment in patients with advanced gastric cancer.
    Clin Cancer Res. 2020 Dec 1. pii: 1078-0432.CCR-20-3559.
    >> Share

    November 2020
  18. PARK J, Jang BG, Kim YW, Park H, et al
    A prospective validation and observer performance study of a deep learning algorithm for pathologic diagnosis of gastric tumors in endoscopic biopsies.
    Clin Cancer Res. 2020 Nov 10. pii: 1078-0432.CCR-20-3159.
    >> Share

    June 2020
  19. XU J, Bai Y, Xu N, Li E, et al
    Tislelizumab Plus Chemotherapy as First-line Treatment for Advanced Esophageal Squamous Cell Carcinoma and Gastric/Gastroesophageal Junction Adenocarcinoma.
    Clin Cancer Res. 2020 Jun 19. pii: 1078-0432.CCR-19-3561.
    >> Share

    April 2020
  20. GALLETTI G, Zhang C, Gjyrezi A, Cleveland K, et al
    Microtubule engagement with taxane is altered in taxane-resistant gastric cancer.
    Clin Cancer Res. 2020 Apr 22. pii: 1078-0432.CCR-19-3018.
    >> Share

  21. KANG YK, Bang YJ, Kondo S, Chung HC, et al
    Safety and Tolerability of Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF-beta and PD-L1, in Asian Patients with Pretreated Recurrent or Refractory Gastric Cancer.
    Clin Cancer Res. 2020 Apr 16. pii: 1078-0432.CCR-19-3806.
    >> Share

    March 2020
  22. KUBOTA Y, Kawazoe A, Sasaki A, Mishima S, et al
    The impact of molecular subtype on efficacy of chemotherapy and checkpoint inhibition in advanced gastric cancer.
    Clin Cancer Res. 2020 Mar 10. pii: 1078-0432.CCR-20-0075.
    >> Share

    February 2020
  23. KELLY RJ, Lee J, Bang YJ, Almhanna K, et al
    Safety and Efficacy of Durvalumab and Tremelimumab Alone or in Combination in Patients with Advanced Gastric and Gastroesophageal Junction Adenocarcinoma.
    Clin Cancer Res. 2020;26:846-854.
    >> Share

  24. SATHE A, Grimes SM, Lau BT, Chen J, et al
    Single cell genomic characterization reveals the cellular reprogramming of the gastric tumor microenvironment.
    Clin Cancer Res. 2020 Feb 14. pii: 1078-0432.CCR-19-3231.
    >> Share

    July 2019
  25. GREALLY M, Chou JF, Chatila WK, Margolis M, et al
    Clinical and molecular predictors of response to immune checkpoint inhibitors in patients with advanced esophagogastric cancer.
    Clin Cancer Res. 2019 Jul 23. pii: 1078-0432.CCR-18-3603.
    >> Share

    April 2019
  26. WON E, Basunia A, Chatila WK, Hechtman JF, et al
    Efficacy of combined VEGFR1-3, PDGFalpha/beta, and FGFR1-3 blockade using nintedanib for esophagogastric cancer.
    Clin Cancer Res. 2019 Apr 5. pii: 1078-0432.CCR-18-3789.
    >> Share

    January 2019
  27. BALTSCHUKAT S, Schacher Engstler B, Huang A, Hao HX, et al
    Capmatinib (INC280) Is Active Against Models of Non-Small Cell Lung Cancer and Other Cancer Types with Defined Mechanisms of MET Activation.
    Clin Cancer Res. 2019 Jan 23. pii: 1078-0432.CCR-18-2814.
    >> Share

  28. XU J, Zhang Y, Jia R, Yue C, et al
    Anti-PD-1 Antibody SHR-1210 Combined with Apatinib for Advanced Hepatocellular Carcinoma, Gastric, or Esophagogastric Junction Cancer: An Open-label, Dose Escalation and Expansion Study.
    Clin Cancer Res. 2019;25:515-523.
    >> Share

Free Medical Abstracts
Privacy Policy

© Amedeo 1997-2016